Date of Award
2027
Document Type
Capstone
Degree Name
Master of Science (MS)
Department
Physician Assistant Studies
Committee Chair
Ashley Kernicky
Abstract
Introduction:
Migraine is a common neurologic disorder that causes substantial disability and negatively affects quality of life worldwide. This literature review evaluates the current evidence regarding the efficacy, safety, and tolerability of rimegepant for the preventive treatment of migraine.
Methods:
PubMed was searched using the key terms migraine, rimegepant, and prevention. After applying predefined eligibility criteria, five studies were included: two randomized controlled trials, one open-label extension study, one post hoc analysis, and one systematic review.
Results:
Overall, the included studies demonstrated that rimegepant significantly reduced monthly migraine days, improved health-related quality of life and patient-reported outcomes, and was generally well tolerated. Long-term follow-up demonstrated sustained efficacy and safety, while the systematic review supported favorable benefit-risk profiles for CGRP-targeted therapies compared with traditional preventive medications.
Discussion:
The available evidence indicates that rimegepant is an effective and generally well-tolerated option for migraine prevention, particularly in patients who have had an inadequate response to conventional preventive therapies. Additional randomized controlled trials directly comparing rimegepant with established therapies are needed to further define its long-term role in migraine management.
Recommended Citation
Payne AN. Rimegepant for Migraine Prevention: A Review of Current Evidence. The PA Department Journal of Medical Science. 2026. https://digitalcommons.gardner-webb.edu/pa-department-journal-of-medical-science/78
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License